MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring

13:07 EDT 7 Aug 2017 | Xconomy

Early clinical trial data for an experimental MyoKardia drug developed to treat a potentially fatal cardiovascular disorder are showing promise, results that now have the company preparing for a larger study to support FDA approval. South San Francisco, CA-based MyoKardia (NASDAQ: MYOK) is testing the drug, mavacamten in patients who have [a potentially deadly?] form […]

Original Article: MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring


More From BioPortfolio on "MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...